

Targeted inference to identify drug repositioning candidates in the Danish health registries

Supplementary

Contents

1	Supplementary Tables	2
2	Supplementary Figures	7

¹ 1 Supplementary Tables

Supplementary Table 1 Data overview for the observational design with the splits in train/valid/test sets.

	Train				Valid				Test			
	Female		Male		Female		Male		Female		Male	
Patients:	901,833	51.29%	856,426	48.71%	64,501	51.28%	61,291	48.72%	322,092	51.26%	306,237	48.74%
Age:												
36-46	240,559	26.67%	237,831	27.77%	17,092	26.50%	17,162	28.00%	85,484	26.54%	85,127	27.80%
46-56	258,033	28.61%	258,120	30.14%	18,420	28.56%	18,260	29.79%	92,020	28.57%	92,593	30.24%
56-66	204,272	22.65%	199,519	23.30%	14,633	22.69%	14,276	23.29%	73,081	22.69%	71,052	23.20%
66-76	149,047	16.53%	126,268	14.74%	10,690	16.57%	9,199	15.01%	53,572	16.63%	45,160	14.75%
76-86	49,922	5.54%	34,688	4.05%	3,666	5.68%	2,394	3.91%	17,935	5.57%	12,305	4.02%
Obs. Period:	8,437,523	1 - 11 - 14	7,920,855	1 - 11 - 14	602,705	1 - 11 - 14	563,748	1 - 10 - 14	3,015,650	1 - 11 - 14	2,830,873	1 - 10 - 14
Unique Diag.	4,621,418	0 - 4 - 16	4,276,183	0 - 3 - 16	330,484	0 - 4 - 16	306,397	0 - 3 - 16	1,647,576	0 - 4 - 16	1,525,370	0 - 3 - 16
Unique Pres.	17,871,825	4 - 17 - 44	13,093,221	2 - 13 - 36	1,277,595	4 - 18 - 44	936,692	2 - 13 - 36	6,378,036	4 - 17 - 44	4,679,747	2 - 13 - 36
Events:												
Dementia	18,731	2.08%	17,321	2.02%	1,303	2.02%	1,263	2.06%	6,743	2.09%	6,279	2.05%
Extrapyramidal	6,594	0.73%	7,671	0.90%	455	0.71%	573	0.93%	2,344	0.73%	2,779	0.91%
CVD	91,671	10.16%	133,700	15.61%	6,635	10.29%	9,580	15.63%	32,818	10.19%	47,506	15.51%
Renal	13,626	1.51%	23,207	2.71%	984	1.53%	1,684	2.75%	4,789	1.49%	8,317	2.72%
COPD	47,915	5.31%	46,070	5.38%	3,463	5.37%	3,265	5.33%	17,166	5.33%	16,412	5.36%
Liver	11,468	1.27%	14,286	1.67%	799	1.24%	1,070	1.75%	4,114	1.28%	5,098	1.66%
IBD	16,313	1.81%	11,718	1.37%	1,204	1.87%	784	1.28%	5,953	1.85%	4,143	1.35%
Cancer	94,895	10.52%	105,562	12.33%	6,884	10.67%	7,571	12.35%	34,201	10.62%	37,771	12.33%
Death	101,615	11.27%	134,759	15.74%	7,192	11.15%	9,813	16.01%	36,165	11.23%	48,157	15.73%
Excluded:												
Dementia	4,421	0.49%	4,566	0.53%	331	0.51%	308	0.50%	1,673	0.52%	1,655	0.54%
Extrapyramidal	2,884	0.32%	2,623	0.31%	212	0.33%	204	0.33%	1,062	0.33%	994	0.32%
CVD	41,656	4.62%	66,726	7.79%	3,028	4.69%	4,813	7.85%	14,912	4.63%	23,643	7.72%
Renal	1,971	0.22%	3,117	0.36%	137	0.21%	217	0.35%	652	0.20%	1,138	0.37%
COPD	20,584	2.28%	18,359	2.14%	1,429	2.22%	1,311	2.14%	7,388	2.29%	6,460	2.11%
Liver	8,820	0.98%	10,550	1.23%	578	0.90%	717	1.17%	3,180	0.99%	3,680	1.20%
IBD	12,465	1.38%	9,565	1.12%	903	1.40%	653	1.07%	4,453	1.38%	3,322	1.08%
Cancer	57,604	6.39%	28,932	3.38%	4,143	6.42%	2,156	3.52%	20,599	6.40%	10,358	3.38%
Death	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

Supplementary Table 2 Data overview for target trial design of ATC:C10AA (Statins) and CVD

Female			Male				
	Level	treat_1 = 0 (n=131608)	treat_1 = 1 (n=8691)	Variable	Level	treat_1 = 0 (n=131608)	treat_1 = 1 (n=8691)
Age_50_55	0	111,761 (74.8)	8,946 (85.2)	Age_50_55	0	96,203 (73.1)	7,181 (82.6)
	1	37629 (25.2)	1553 (14.8)		1	35405 (26.9)	1510 (17.4)
Age_55_60	0	115,723 (77.5)	8,499 (81.0)	Age_55_60	0	31,055 (23.6)	1,803 (20.7)
	1	33667 (22.5)	2000 (19.0)		1	100553 (76.4)	6888 (79.3)
Age_60_65	0	117,429 (78.6)	7,804 (74.3)	Age_60_65	0	102,445 (77.8)	6,445 (74.2)
	1	31961 (21.4)	2695 (25.7)		1	29163 (22.2)	2246 (25.8)
Age_65_70	0	128,816 (86.2)	8,484 (80.8)	Age_65_70	0	114,162 (86.7)	7,141 (82.2)
	1	20574 (13.8)	2015 (19.2)		1	17446 (13.3)	1550 (17.8)
Age_70_75	0	14,688 (9.8)	1,322 (12.6)	Age_70_75	0	120,403 (91.5)	7,641 (87.9)
	1	134702 (90.2)	9177 (87.4)		1	11205 (8.5)	1050 (12.1)
Age_75_80	0	138,519 (92.7)	9,585 (91.3)	Age_75_80	0	124,274 (94.4)	8,159 (93.9)
	1	10871 (7.3)	914 (8.7)		1	7334 (5.6)	532 (6.1)
censor_1	uncensored	148,711 (99.5)	10,462 (99.6)	censor_1	uncensored	130,784 (99.4)	8,647 (99.5)
	censored	679 (0.5)	37 (0.4)		censored	824 (0.6)	44 (0.5)
censor_2	uncensored	147,990 (99.1)	10,414 (99.2)	censor_2	uncensored	129,944 (98.7)	8,593 (98.9)
	censored	1400 (0.9)	85 (0.8)		censored	1664 (1.3)	98 (1.1)
censor_3	uncensored	147,278 (98.6)	10,375 (98.8)	censor_3	uncensored	129,138 (98.1)	8,545 (98.3)
	censored	2112 (1.4)	124 (1.2)		censored	2470 (1.9)	146 (1.7)
censor_4	uncensored	146,594 (98.1)	10,340 (98.5)	censor_4	uncensored	128,290 (97.5)	8,488 (97.7)
	censored	2796 (1.9)	159 (1.5)		censored	3318 (2.5)	203 (2.3)
censor_5	uncensored	145,885 (97.7)	10,292 (98.0)	censor_5	uncensored	127,443 (96.8)	8,442 (97.1)
	censored	3505 (2.3)	207 (2.0)		censored	4165 (3.2)	249 (2.9)
censor_6	uncensored	145,162 (97.2)	10,245 (97.6)	censor_6	uncensored	126,651 (96.2)	8,392 (96.6)
	censored	4228 (2.8)	254 (2.4)		censored	4957 (3.8)	299 (3.4)
event_1	0	148,603 (99.5)	10,407 (99.1)	event_1	0	130,411 (99.1)	8,585 (98.8)
	1	787 (0.5)	92 (0.9)		1	1197 (0.9)	106 (1.2)
event_2	0	147,857 (99.0)	10,341 (98.5)	event_2	0	129,245 (98.2)	8,488 (97.7)
	1	1533 (1.0)	158 (1.5)		1	2363 (1.8)	203 (2.3)
event_3	0	146,999 (98.4)	10,272 (97.8)	event_3	0	128,081 (97.3)	8,408 (96.7)
	1	2391 (1.6)	227 (2.2)		1	3527 (2.7)	283 (3.3)
event_4	0	146,081 (97.8)	10,196 (97.1)	event_4	1	4,744 (3.6)	394 (4.5)
	1	3309 (2.2)	303 (2.9)		0	126864 (96.4)	8297 (95.5)
event_5	0	145,200 (97.2)	10,125 (96.4)	event_5	1	5,881 (4.5)	494 (5.7)
	1	4190 (2.8)	374 (3.6)		0	125727 (95.5)	8197 (94.3)
event_6	0	144,330 (96.6)	10,068 (95.9)	event_6	1	7,071 (5.4)	579 (6.7)
	1	5060 (3.4)	431 (4.1)		0	124537 (94.6)	8112 (93.3)
Covars	mean (sd)	9.7 (7.3)	13.4 (7.8)	Covars	mean (sd)	6.9 (5.8)	10.6 (6.1)
Total covars:	243			Total covars:	203		

Supplementary Table 3 Concordance index for the Cox regression across the different data splits

Targets	Concordance Female	Concordance Female sd.	Concordance Male	Concordance Male sd.
Train				
Dementia	0.709	0.002	0.730	0.002
Extrapyramidal	0.747	0.004	0.751	0.004
CVD	0.672	0.001	0.635	0.001
Renal	0.808	0.002	0.780	0.002
COPD	0.684	0.001	0.622	0.002
Liver	0.663	0.003	0.672	0.002
IBD	0.612	0.002	0.595	0.003
Cancer	0.558	0.001	0.562	0.001
Death	0.799	0.001	0.772	0.001
Valid				
Dementia	0.703	0.008	0.728	0.008
Extrapyramidal	0.739	0.014	0.755	0.013
CVD	0.670	0.004	0.636	0.003
Renal	0.798	0.008	0.770	0.007
COPD	0.679	0.005	0.626	0.006
Liver	0.664	0.011	0.682	0.009
IBD	0.617	0.009	0.603	0.011
Cancer	0.553	0.004	0.555	0.004
Death	0.799	0.003	0.768	0.003
Test				
Dementia	0.702	0.004	0.734	0.004
Extrapyramidal	0.741	0.006	0.740	0.006
CVD	0.669	0.002	0.634	0.001
Renal	0.798	0.004	0.775	0.003
COPD	0.684	0.002	0.620	0.003
Liver	0.666	0.005	0.673	0.004
IBD	0.615	0.004	0.608	0.005
Cancer	0.552	0.002	0.560	0.002
Death	0.798	0.001	0.774	0.001


Supplementary Table 4 Pearson correlation for Bayesian Cox estimates between females and males.

Targets	Pearson Correlation
0 Dementia	0.657
1 Ext.pyram.	0.861
2 CVD	0.668
3 Renal	0.79
4 COPD	0.638
5 Liver	0.723
6 IBD	0.722
7 Cancer	0.459
8 Death	0.803





Supplementary Table 5 Pearson correlation for ATE estimates between Females and Males.

	Targets	Pearson Correlation
0	Dementia	0.603
1	Ext.pyram.	0.205
2	CVD	0.629
3	Renal	0.46
4	COPD	0.577
5	Liver	0.22
6	IBD	0.22
7	Cancer	0.129
8	Death	0.785


² 2 Supplementary Figures




Supplementary Figure 1 Significant (CI: 95%) effect estimates for the Bayesian Cox regression and Ltmle for Dementia




Supplementary Figure 2 Significant (CI: 95%) effect estimates for the Bayesian Cox regression and Ltmle for Extrapyramidal disorders




Supplementary Figure 3 Significant (CI: 95%) effect estimates for the Bayesian Cox regression and Ltmle for CVD







Supplementary Figure 4 Significant (CI: 95%) effect estimates for the Bayesian Cox regression and Ltmle for Renal failure






Supplementary Figure 6 Significant (CI: 95%) effect estimates for the Bayesian Cox regression and Ltmle for Liver disease




Supplementary Figure 7 Significant (CI: 95%) effect estimates for the Bayesian Cox regression and Ltmle for IBD




Supplementary Figure 8 Significant (CI: 95%) effect estimates for the Bayesian Cox regression and Ltmle for Cancer



Supplementary Figure 9 Significant (CI: 95%) effect estimates for the Bayesian Cox regression and Ltmle for Death



Supplementary Figure 10 Effect estimates for ATC:A10AB for the observational Bayesian Cox regression on the left hand side and the Ltmle analysis on the right hand side for both sexes.



Supplementary Figure 11 Effect estimates by sex for the observational Bayesian Cox regression and for Ltmle analysis summarized by ATC drug, showing all with at least 3 significant effects.